Tarsus Pharmaceuticals, Inc. (TARS) Stock Forecast
TARS analyst forecast
as of October 18, 2026- Analyst consensus
- Strong buy 4.90 / 5 from 10 analysts
- Price target
- $99.80 average of analyst targets
- Upside to target
- +46.6% from the latest close
- Next earnings
- November 3, 2026 EPS estimate $-1.43
- 52-week range
- $56.11 – $90.78
TARS analyst ratings
10 analystsNumber of analysts at each rating.
TARS price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
TARS earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.73 | −$2.01 | −$1.46 | −$0.30 | −476.7% | 4 |
| Current fiscal year (2026) | −$4.88 | −$11.63 | −$2.15 | −$1.59 | −207.1% | 4 |
| Next fiscal year (2027) | −$0.50 | −$1.59 | $1.04 | −$4.88 | +89.8% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
TARS revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $187.5M | $178.7M | $193.5M | +57.9% | 5 |
| Current fiscal year (2026) | $727.5M | $706.5M | $738.0M | +61.2% | 5 |
| Next fiscal year (2027) | $920.0M | $890.0M | $958.3M | +26.5% | 4 |
TARS EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
TARS revenue: reported and forecast
TARS EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$1.83 | −$1.53 | −$1.54 | −$1.77 | −$1.73 | −5.7% | 0 up · 0 down |
| Current fiscal year (2026) | −$2.25 | −$2.13 | −$2.10 | −$5.77 | −$4.88 | +117.0% | 0 up · 0 down |
| Next fiscal year (2027) | $1.66 | $2.33 | $2.42 | −$0.36 | −$0.50 | −130.1% | 0 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
TARS earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; TARS beat in 7 of 12.
What analysts expect from TARS
10 analysts cover Tarsus Pharmaceuticals; their consensus rating is strong buy (4.90 on a 1–5 scale, where 5 is a strong buy). The average price target is $99.80, 46.6% above the latest close of $68.07. Analysts expect earnings of −$4.88 per share for 2026, −207.1% from a year earlier. For 2027 the average estimate is −$0.50 per share on revenue of $920.0 million. Tarsus Pharmaceuticals beat the EPS estimate in 7 of the last 12 quarters.
Related: TARS income statement, TARS key metrics, TARS chart. See the TARS stock overview for the latest quote and news.
TARS forecast FAQ
What is Tarsus Pharmaceuticals's price target?
The average analyst price target for Tarsus Pharmaceuticals is $99.80, 46.6% above the latest close of $68.07.
Is Tarsus Pharmaceuticals a buy, hold or sell?
Of 10 analysts covering Tarsus Pharmaceuticals, 9 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Tarsus Pharmaceuticals's EPS forecast?
Analysts forecast −$4.88 per share for 2026 (range −$11.63 to −$2.15); for 2027 the estimate is −$0.50.
What is Tarsus Pharmaceuticals's revenue forecast?
The average revenue estimate for 2026 is $727.5 million, growth of 61.2%; for 2027 it is $920.0 million.
When does Tarsus Pharmaceuticals report earnings?
Tarsus Pharmaceuticals is expected to report results for the quarter ending September 30, 2026 on November 3, 2026; the EPS estimate is $-1.43.
Does Tarsus Pharmaceuticals usually beat earnings estimates?
Tarsus Pharmaceuticals reported EPS at or above the analyst estimate in 7 of the last 12 quarters.